Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in Neurology Retrieve available abstracts of 217 articles: HTML format

Single Articles

August 2025
1. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
   Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
   Neurology. 2025;105:e213909.
   PubMed    
   
   
   July 2025
2. WU L, Jiang W, Du R, Liu Y, et al
   Clinical Reasoning: Acute and Progressive Cognitive Decline in a 38-Year-Old Man.
   Neurology. 2025;105:e213871.
   PubMed     Abstract available
   
   
   
3. PETERSSON M, Jons D, Feresiadou A, Ilinca A, et al
   Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG Study.
   Neurology. 2025;105:e213771.
   PubMed     Abstract available
   
   
   
4. ZHOU J, Nilius S, Pilipczuk O, Scowcroft A, et al
   Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases.
   Neurology. 2025;105:e213736.
   PubMed     Abstract available
   
   
   
5. JIA A, Price TR, Rosner J, Broderick C, et al
   Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
   Neurology. 2025;105:e213663.
   PubMed     Abstract available
   
   
   June 2025
6. GOYNE C, Fair AE, Yilmaz D, Race J, et al
   Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
   Neurology. 2025;104:e213673.
   PubMed     Abstract available
   
   
   
7. JUL JARBAEK NIELSEN J, Levison L, Andersen H
   Mortality in Myasthenia Gravis in Denmark From 1985 to 2020: A Population-Based Cohort Study.
   Neurology. 2025;104:e213745.
   PubMed     Abstract available
   
   
   
8. YEH EA
   Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
   Neurology. 2025;104:e213840.
   PubMed    
   
   
   
9. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
   Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
   Neurology. 2025;104:e213650.
   PubMed     Abstract available
   
   
   May 2025
10. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2025;104:e213618.
    PubMed     Abstract available
    
    
    
11. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
    Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
    Neurology. 2025;104:e213607.
    PubMed     Abstract available
    
    
    
12. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
    Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
    Neurology. 2025;104:e213558.
    PubMed     Abstract available
    
    
    
13. FOX RJ, Rudick RA
    A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
    Neurology. 2025;104:e213672.
    PubMed    
    
    
    
14. DINOTO A, Cacciaguerra L, Vorasoot N, Redenbaugh V, et al
    Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Neurology. 2025;104:e213557.
    PubMed     Abstract available
    
    
    
15. VU AP, Kapadia RK, Roberts JI
    Pearls & Oy-sters: Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Presenting as Encephalomyelitis With Leptomeningeal Enhancement.
    Neurology. 2025;104:e213662.
    PubMed     Abstract available
    
    
    
16. MARRIE RA, Sharma M, Cutter GR, Fox RJ, et al
    Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing.
    Neurology. 2025;104:e213587.
    PubMed     Abstract available
    
    
    
17. CHAGGAR G, Waldner D, Scozzafava J, Harrison R, et al
    Teaching NeuroImage: Severe Enterovirus Encephalitis as a Complication of Ocrelizumab Treatment for Multiple Sclerosis.
    Neurology. 2025;104:e213585.
    PubMed    
    
    
    
18. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;104:e213574.
    PubMed     Abstract available
    
    
    
19. ZARA P, Chessa P, Deiana GA, Morette AM, et al
    Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice.
    Neurology. 2025;104:e213498.
    PubMed     Abstract available
    
    
    
20. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
    Updated Multiple Sclerosis Incidence in France, 2011-2021.
    Neurology. 2025;104:e213586.
    PubMed     Abstract available
    
    
    April 2025
21. ZELIKOVICH AS, Zamorska B, Michaelson NM
    Patient Perspectives: Patient as Teacher: The Impact of Listening to a Patient With Stiff-Person Syndrome on Her Disease Course.
    Neurology. 2025;104:e213433.
    PubMed     Abstract available
    
    
    
22. NAKAJIMA A, Hokari M, Yanagimura F, Saji E, et al
    Long-Term Clinical Landscapes of Spinal Hypertrophic Pachymeningitis With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Neurology. 2025;104:e213420.
    PubMed     Abstract available
    
    
    
23. AL-SALAHAT A, Abdul Jabbar AB, Sharma R, Chen YT, et al
    Demographic and Geographic Trends in Myasthenia Gravis-Related Mortality in the United States, 1999-2022.
    Neurology. 2025;104:e213505.
    PubMed     Abstract available
    
    
    
24. ABBOUD H, Clardy SL, Dubey D, Wickel J, et al
    The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and Opportunities.
    Neurology. 2025;104:e213487.
    PubMed     Abstract available
    
    
    
25. BROWNLEE WJ, Foster MA, Pontillo G, Davagnanam I, et al
    Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
    Neurology. 2025;104:e210274.
    PubMed     Abstract available
    
    
    
26. GANESH A, Galetta SL
    Editors' Note: Domestic Violence and Abuse in People Living With Multiple Sclerosis.
    Neurology. 2025;104:e213407.
    PubMed    
    
    
    
27. VIDAL-JORDANA A, Ontaneda D
    To Kill Time: A Bold Step Toward Simplifying Multiple Sclerosis Diagnosis.
    Neurology. 2025;104:e213416.
    PubMed    
    
    
    
28. MAHAJAN KR, Herman D, Zheng Y, Androjna C, et al
    Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
    Neurology. 2025;104:e210259.
    PubMed     Abstract available
    
    
    
29. MAVRIDIS A, Viktorisson A, Eliasson B, von Euler M, et al
    Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes: A Nationwide Cohort Study in Sweden.
    Neurology. 2025;104:e213480.
    PubMed     Abstract available
    
    
    
30. MCAREE M, Frontera JA
    Clinical Reasoning: A 56-Year-Old Woman With New-Onset Hoarseness and Dysphagia.
    Neurology. 2025;104:e213363.
    PubMed     Abstract available
    
    
    March 2025
31. GOH WGW, Ng IKS, Tan MKX, Fong CYK, et al
    Clinical Reasoning: A 26-Year-Old Woman With Headache and Eosinophilia.
    Neurology. 2025;104:e213434.
    PubMed     Abstract available
    
    
    
32. MAILLART E, Dubessy AL, Shor N, Piljan M, et al
    Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e213399.
    PubMed     Abstract available
    
    
    
33. GOMEZ-FIGUEROA E, Moreno-Bernardino CJ, De Alba-Sanchez AM, Guerrero-Udave N, et al
    The Burden of Multiple Sclerosis in Mexico.
    Neurology. 2025;104:e213343.
    PubMed     Abstract available
    
    
    February 2025
34. TRANFA M, Petracca M, Moccia M, Scaravilli A, et al
    Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.
    Neurology. 2025;104:e213349.
    PubMed     Abstract available
    
    
    
35. MARRIE RA, Bolton J, Ling YV, Bernstein C, et al
    Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
    Neurology. 2025;104:e210170.
    PubMed     Abstract available
    
    
    
36. DERSCH RS, Fingerle V, Berns J, Rauer S, et al
    Pearls & Oy-sters: Recurrent Lyme Neuroborreliosis With Seroreversion in a Patient With Multiple Sclerosis on a B-Cell Depleting Therapy.
    Neurology. 2025;104:e213330.
    PubMed     Abstract available
    
    
    
37. ROSS LA
    Peripartum Mental Illness in Mothers With Multiple Sclerosis Merits Neurologists' Attention.
    Neurology. 2025;104:e213366.
    PubMed    
    
    
    
38. CERQUEIRA JJ, Berthele A, Cree BAC, Filippi M, et al
    Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
    Neurology. 2025;104:e210142.
    PubMed     Abstract available
    
    
    
39. COBO-CALVO A, Carbonell-Mirabent P, Tur C, Otero-Romero S, et al
    Age-Related Disability Outcomes After a First Demyelinating Event.
    Neurology. 2025;104:e210305.
    PubMed     Abstract available
    
    
    
40. KRYSKO KM, Waltz M, Chitnis T, Weinstock-Guttman B, et al
    Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.
    Neurology. 2025;104:e210213.
    PubMed     Abstract available
    
    
    
41. ROCCA MA, Preziosa P, Filippi M
    Age Matters in Multiple Sclerosis: Novel Insights Into Disease Progression From Clinical Onset.
    Neurology. 2025;104:e213396.
    PubMed    
    
    
    
42. BRENTON JN
    Menarche and Relapses in Multiple Sclerosis: Associations Between a Physiologic Developmental Milestone and Disease Activity.
    Neurology. 2025;104:e213321.
    PubMed    
    
    
    
43. BALCOM EF, Mccombe JA, Kate MP, Vu K, et al
    Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.
    Neurology. 2025;104:e210251.
    PubMed     Abstract available
    
    
    
44. CARVAJAL R, Guananga-Alvarez D, Tur C, Esperalba J, et al
    Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
    Neurology. 2025;104:e210281.
    PubMed     Abstract available
    
    
    
45. AMEZCUA L, Cardenas-Iniguez C, Orlando C, Martinez A, et al
    Person-Centered Social Determinants and Neighborhood-Level Deprivation Associated With Disability in Hispanic People With Multiple Sclerosis.
    Neurology. 2025;104:e213332.
    PubMed     Abstract available
    
    
    
46. 
    Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis.
    Neurology. 2025;104:e210299.
    PubMed    
    
    
    
47. 
    Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
    Neurology. 2025;104:e210298.
    PubMed    
    
    
    January 2025
48. TSAI CC, Chen J, Pikula A, Johnson EL, et al
    Opinion & Special Articles: Beyond Pronouns-Educating Trainees on the Impact of Language on Gender Inclusivity in Neurologic Practice.
    Neurology. 2025;104:e210289.
    PubMed     Abstract available
    
    
    
49. SILVERMAN HE, Bostrom A, Nylander AN, Akula A, et al
    Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
    Neurology. 2025;104:e210228.
    PubMed     Abstract available
    
    
    
50. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
    Neurology. 2025;104:e210149.
    PubMed     Abstract available
    
    
    
51. CARVALHO IV, Gomes F, Almendra L, Geraldo A, et al
    Reversible Unilateral Tongue Border Atrophy Associated With Anti-Acetylcholine Receptor Antibody-Positive Myasthenia Gravis.
    Neurology. 2025;104:e210288.
    PubMed    
    
    
    
52. CAGOL A, Montobbio N
    Reassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
    Neurology. 2025;104:e210272.
    PubMed    
    
    
    
53. CRUCIANI A, Toosy AT
    Progression Independent of Relapse Activity in Multiple Sclerosis: More, or Less, Than Meets the Eye?
    Neurology. 2025;104:e210296.
    PubMed    
    
    
    
54. STRIJBIS EMM, Mostert J, Comtois J, Salter A, et al
    Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;104:e210153.
    PubMed     Abstract available
    
    
    
55. WONG SH, Abuzaitoun R, Cornblath WT, Eggenberger ER, et al
    Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire.
    Neurology. 2025;104:e210150.
    PubMed     Abstract available
    
    
    
56. MONGAY-OCHOA N, Pareto D, Alberich M, Carbonell-Mirabent P, et al
    Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis.
    Neurology. 2025;104:e210136.
    PubMed     Abstract available
    
    
    
57. CHEN B, Francis A, Cooper SA, Dobson R, et al
    Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e210137.
    PubMed     Abstract available
    
    
    
58. JUL JARBAEK NIELSEN J, Levison L, Andersen H
    Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021: A Nationwide Population-Based Study.
    Neurology. 2025;104:e210139.
    PubMed     Abstract available
    
    
    December 2024
59. RIMKUS CM, Nucci MP, Avolio IB, Apostolos-Pereira SL, et al
    Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.
    Neurology. 2024;103:e210080.
    PubMed     Abstract available
    
    
    
60. BRENNER J, Ruhe CJ, Kulderij I, Bastiaansen AEM, et al
    Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis.
    Neurology. 2024;103:e210109.
    PubMed     Abstract available
    
    
    
61. SIRIRATNAM P, Huda S, Van Der Walt A, Sanfilippo PG, et al
    Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
    Neurology. 2024;103:e209940.
    PubMed     Abstract available
    
    
    
62. ROSS R, O'Neill KA, Betensky RA, Billiet T, et al
    Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.
    Neurology. 2024;103:e210140.
    PubMed     Abstract available
    
    
    
63. HARTUNG HP, Benedict RHB, Berger T, Bermel RA, et al
    Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
    Neurology. 2024;103:e210049.
    PubMed     Abstract available
    
    
    
64. CRANE PD, Sillau S, Dreher R, Fix R, et al
    Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System.
    Neurology. 2024;103:e210078.
    PubMed     Abstract available
    
    
    
65. KLEIN CJ, Triplett JD, Murray DL, Gorsh AP, et al
    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.
    Neurology. 2024;103:e210000.
    PubMed     Abstract available
    
    
    
66. QUINN CM, Rajarajan P, Gill AJ, Kopinsky H, et al
    Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
    Neurology. 2024;103:e210003.
    PubMed     Abstract available
    
    
    
67. WILSON E, Meeks HD, Barney BJ, Waltz M, et al
    Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.
    Neurology. 2024;103:e209991.
    PubMed     Abstract available
    
    
    November 2024
68. REEVES JA, Bartnik A, Jakimovski D, Mohebbi M, et al
    Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
    Neurology. 2024;103:e210004.
    PubMed     Abstract available
    
    
    
69. WATANABE M, Isobe N, Niino M, Nakashima I, et al
    Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
    Neurology. 2024;103:e209992.
    PubMed     Abstract available
    
    
    
70. SANTILLI AR, Ni O, Milone M, Selcen D, et al
    Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy.
    Neurology. 2024;103:e210001.
    PubMed     Abstract available
    
    
    
71. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    PubMed     Abstract available
    
    
    
72. SHARMA R, Bellacicco NJ, Husar WG, Park JH, et al
    Pearls & Oy-sters: Breaking Bad CIDP: Recognition of Anti-NF155 Autoimmune Nodopathy in Refractory CIDP.
    Neurology. 2024;103:e209848.
    PubMed    
    
    
    
73. MICHAELSON NM, Klawiter EC, Singhal T
    Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
    Neurology. 2024;103:e210047.
    PubMed    
    
    
    
74. PONTILLO G, Prados F, Colman J, Kanber B, et al
    Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
    Neurology. 2024;103:e209976.
    PubMed     Abstract available
    
    
    
75. BRUCKMAN D, Lee I, Schold JD, Claytor BR, et al
    Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019.
    Neurology. 2024;103:e210005.
    PubMed     Abstract available
    
    
    
76. 
    Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
    Neurology. 2024;103:e209968.
    PubMed    
    
    
    
77. BROEDERS TAA, van Dam M, Pontillo G, Rauh V, et al
    Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.
    Neurology. 2024;103:e209952.
    PubMed     Abstract available
    
    
    
78. PIERRET C, Mulliez A, Le Bihan-Benjamin C, Moisset X, et al
    Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2024;103:e209885.
    PubMed     Abstract available
    
    
    
79. GUPTA J, Choudhary R, Gupta A, Sharma P, et al
    Child Neurology: Acute Necrotizing Encephalopathy of Childhood Associated With Dengue: Good Neurologic Outcome Despite a Fulminant Presentation.
    Neurology. 2024;103:e209954.
    PubMed     Abstract available
    
    
    
80. SIEGLER JE, Galetta SL
    Editors' Note: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209934.
    PubMed    
    
    
    
81. MOEHLMAN M
    Author Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209565.
    PubMed    
    
    
    
82. YANG Y, Li J, Tang Y
    Reader Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209545.
    PubMed    
    
    
    
83. MARIGNIER R, Kunchok A
    Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines.
    Neurology. 2024;103:e209970.
    PubMed    
    
    
    
84. RINGELSTEIN M, Asseyer S, Lindenblatt G, Fischer K, et al
    Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
    Neurology. 2024;103:e209888.
    PubMed     Abstract available
    
    
    October 2024
85. SILVERMAN A, Sasaki M, Espindola Lima JE, Cheronis C, et al
    Child Neurology: Remarkable Recovery From Severe Acute Necrotizing Encephalopathy.
    Neurology. 2024;103:e209877.
    PubMed     Abstract available
    
    
    
86. XU TT, Kaplan TM, Chen JJ
    Teaching NeuroImages: Cilioretinal Artery Occlusion Secondary to Antiphospholipid Syndrome.
    Neurology. 2024;103:e209901.
    PubMed    
    
    
    
87. SIEGLER JE 3RD, Galetta S
    Editors' Note: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209893.
    PubMed    
    
    
    
88. GROBOIS L, You M, Etienne M
    Reader Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209508.
    PubMed    
    
    
    
89. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Author Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209515.
    PubMed    
    
    
    
90. HAY M, Rollot F, Casey R, Kerbrat A, et al
    Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
    Neurology. 2024;103:e209886.
    PubMed     Abstract available
    
    
    
91. YOKOTE H, Mori K, Nakamichi K, Matsuda T, et al
    Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
    Neurology. 2024;103:e209874.
    PubMed    
    
    
    
92. ROBERTS JI, Ng D, Kapadia R
    Pearls & Oy-sters: Tumour-Like Mass Lesion Secondary to Primary CNS Vasculitis.
    Neurology. 2024;103:e209819.
    PubMed     Abstract available
    
    
    
93. 
    Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015).
    Neurology. 2024;103:e209905.
    PubMed    
    
    
    
94. 
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;103:e209461.
    PubMed    
    
    
    
95. LOONSTRA FC, Alvarez Sirvent D, Tesi N, Holstege H, et al
    Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year Cohort.
    Neurology. 2024;103:e209663.
    PubMed     Abstract available
    
    
    
96. BLACKOWICZ M, James J, McNeil-Posey K, Schwartz T, et al
    Socioeconomic Factors Associated with >/=2-year Delayed Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States.
    Neurology. 2024;103.
    PubMed     Abstract available
    
    
    
97. MANGIORIS G, Orozco E, Dubey D, Flanagan E, et al
    Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study.
    Neurology. 2024;103.
    PubMed     Abstract available
    
    
    
98. VENKATARAMAN I, Ott A, Miske R, Scharf M, et al
    Performance Assessment of the New EUROLINE Neurologic Syndrome 15 Ag (IgG) for the Determination of Autoantibodies Associated with Neurological Disorders.
    Neurology. 2024;103.
    PubMed     Abstract available
    
    
    September 2024
99. ROHM Z, Mobley B, Pawate S
    Teaching NeuroImage: Immunoglobulin G4-Related Hypophysitis.
    Neurology. 2024;103:e209809.
    PubMed    
    
    
    
100. ROVIRA A, Pareto D
     chi-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis: Divide and Conquer.
     Neurology. 2024;103:e209735.
     PubMed    
     
     
     
101. MULLER J, Lu PJ, Cagol A, Ruberte E, et al
     Quantifying Remyelination Using chi-Separation in White Matter and Cortical Multiple Sclerosis Lesions.
     Neurology. 2024;103:e209604.
     PubMed     Abstract available
     
     
     
102. BOURDETTE D
     Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment.
     Neurology. 2024;103:e209835.
     PubMed    
     
     
     
103. BSTEH G, Aicher ML, Walde JF, Krajnc N, et al
     Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
     Neurology. 2024;103:e209752.
     PubMed     Abstract available
     
     
     
104. BANKS SA, Brinjikji W, Giannini C, Syc-Mazurek SB, et al
     Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions.
     Neurology. 2024;103:e209739.
     PubMed    
     
     
     
105. ZARA P, Solla P, Damato V, Sechi E, et al
     Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis.
     Neurology. 2024;103:e209756.
     PubMed    
     
     
     
106. SHIMIZU A, Noguchi-Shinohara M, Komatsu J, Ono K, et al
     Multifocal Intracranial Rosai-Dorfman Disease Mimicking Immunoglobulin G4-Related Pachymeningitis.
     Neurology. 2024;103:e209741.
     PubMed    
     
     
     
107. ABBOUD H, Farez MF
     The Risk of Multiple Sclerosis Relapse After Vaccination: Can a Population-Based Study of Mass Vaccination End the Longstanding Debate?
     Neurology. 2024;103:e209761.
     PubMed    
     
     
     
108. MOISSET X, Leray E, Chenaf C, Taithe F, et al
     Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
     Neurology. 2024;103:e209662.
     PubMed     Abstract available
     
     
     August 2024
109. KARALIUS M, Mohan S, Paredes D, Rasool N, et al
     Pearls & Oy-sters: Optic Neuritis as First Demyelinating Event During Pregnancy in 2 Young Hispanic Women: MS vs MOGAD.
     Neurology. 2024;103:e209706.
     PubMed     Abstract available
     
     
     
110. PASCUAL-GONI E, Caballero-Avila M, Querol L
     Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
     Neurology. 2024;103:e209725.
     PubMed     Abstract available
     
     
     
111. MENON D, Alharbi M, Katzberg HD, Bril V, et al
     Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
     Neurology. 2024;103:e209722.
     PubMed     Abstract available
     
     
     
112. TAGA A, Wali A, Eberhart CG, Green KE, et al
     Teaching NeuroImage: Giant Cell Arteritis With Optic Perineuritis.
     Neurology. 2024;103:e209707.
     PubMed    
     
     
     
113. WANG W
     Reader Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;103:e209441.
     PubMed    
     
     
     
114. WU J, Guo K, Liu J
     Author Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;103:e209463.
     PubMed    
     
     
     
115. LEWIS A, Galetta SL
     Editors' Note: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;103:e209736.
     PubMed    
     
     
     
116. 
     Characterization Profiles of ANCA-associated Vasculitis With Neurological Manifestations (P7-14.007).
     Neurology. 2024;103:e209640.
     PubMed    
     
     
     
117. 
     Artificial Intelligence-Based Ocular Motor Biomarkers for Myasthenia Gravis Diagnosis (P10-11.016).
     Neurology. 2024;103:e209639.
     PubMed    
     
     
     
118. MAYCOCK TJ, Rossor T, Vanegas M, Gringras P, et al
     Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.
     Neurology. 2024;103:e209598.
     PubMed     Abstract available
     
     
     
119. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
     Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
     Neurology. 2024;103:e209677.
     PubMed     Abstract available
     
     
     
120. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
     Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
     Neurology. 2024;103:e209610.
     PubMed     Abstract available
     
     
     July 2024
121. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
     Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
     Neurology. 2024;103:e209574.
     PubMed     Abstract available
     
     
     
122. GRANGEON L, Boulouis G, Capron J, Bala F, et al
     Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.
     Neurology. 2024;103:e209548.
     PubMed     Abstract available
     
     
     
123. GAVAZZI F, Vaia Y, Woidill S, Formanowski B, et al
     Nonverbal Cognitive Skills in Children With Aicardi Goutieres Syndrome.
     Neurology. 2024;103:e209541.
     PubMed     Abstract available
     
     
     
124. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
     Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
     Neurology. 2024;103:e209444.
     PubMed     Abstract available
     
     
     
125. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
     Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
     Neurology. 2024;103:e209543.
     PubMed     Abstract available
     
     
     June 2024
126. KAMINSKI HJ, Kusner LL, Cutter GR, Le Panse R, et al
     Does Surgical Removal of the Thymus Have Deleterious Consequences?
     Neurology. 2024;102:e209482.
     PubMed     Abstract available
     
     
     
127. PALLADINO R, Monasta L
     Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
     Neurology. 2024;102:e209521.
     PubMed    
     
     
     
128. ZHANG C, Liu W, Wang L, Wang F, et al
     Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
     Neurology. 2024;102:e209351.
     PubMed     Abstract available
     
     
     May 2024
129. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
     Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
     Neurology. 2024;102:e209303.
     PubMed     Abstract available
     
     
     
130. SILBERMANN E, Spain RI
     Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
     Neurology. 2024;102:e209456.
     PubMed    
     
     
     
131. FOX RJ, Cree BAC, de Seze J, Gold R, et al
     Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e209357.
     PubMed     Abstract available
     
     
     
132. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
     Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
     Neurology. 2024;102:e209395.
     PubMed     Abstract available
     
     
     
133. LIAO J, Lu Y, Lu Y, Huang Y, et al
     Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
     Neurology. 2024;102:e209302.
     PubMed     Abstract available
     
     
     
134. MICHAELSON NM
     Right Brain: The Unraveling.
     Neurology. 2024;102:e209492.
     PubMed     Abstract available
     
     
     
135. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
     Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
     Neurology. 2024;102:e209350.
     PubMed     Abstract available
     
     
     
136. TANG A, Yoshida K, Lahey H, Wilcox DR, et al
     Herpes Simplex Virus Encephalitis in Patients With Autoimmune Conditions or Exposure to Immunomodulatory Medications.
     Neurology. 2024;102:e209297.
     PubMed     Abstract available
     
     
     April 2024
137. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
     Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
     Neurology. 2024;102:e209282.
     PubMed     Abstract available
     
     
     
138. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
     Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
     Neurology. 2024;102:e209284.
     PubMed    
     
     
     
139. MOEHLMAN M, Kornbluh AB
     Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
     Neurology. 2024;102:e209259.
     PubMed    
     
     
     
140. 
     Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
     Neurology. 2024;102:e209214.
     PubMed    
     
     
     
141. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
     Pathologic Features of Anti-Ku Myositis.
     Neurology. 2024;102:e209268.
     PubMed     Abstract available
     
     
     
142. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
     MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
     Neurology. 2024;102:e209199.
     PubMed     Abstract available
     
     
     
143. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
     Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
     Neurology. 2024;102:e208114.
     PubMed     Abstract available
     
     
     
144. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
     Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
     Neurology. 2024;102:e209245.
     PubMed    
     
     
     
145. THAKOLWIBOON S, Dubey D
     Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
     Neurology. 2024;102:e209213.
     PubMed    
     
     
     
146. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
     Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
     Neurology. 2024;102:e208101.
     PubMed     Abstract available
     
     
     
147. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
     Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
     Neurology. 2024;102:e209257.
     PubMed    
     
     
     
148. AGYEI P, Chen M, Guo Y, Perez CA, et al
     Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
     Neurology. 2024;102:e209187.
     PubMed     Abstract available
     
     
     
149. KUHLMANN G, Cloud B
     Characterization of the Earliest Adopters of Subcutaneous FcRn Blockers for gMG (P4-14.013).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
150. YU Y, Kushlaf H
     Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
151. MASCANFRONI I, Manasson J, Pellerin A, Sanmarco L, et al
     Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases (P4-14.018).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
152. WATANABE F, Fedorko J, Imitola J
     Dimethyl Fumarate Enhances Neural Stem Cell (NSC) Self-renewal and Neuroprotection in a Human Cellular Model of Multiple Sclerosis Inflammation-induced Neurodegeneration (P8-6.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
153. OHRN S, Patel R, Ali A, Bauerschmidt A, et al
     Autonomic Dysfunction in Autoimmune Encephalitis: A Review of the Literature (P6-14.004).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
154. ZAJNER C, Patil N, McInnis R, Van Uum S, et al
     Patterns of Extraocular Muscle Enlargement in Graves' Disease and Acromegaly (P7-10.005).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
155. ROBERTS K, Cohn B, Sista SR
     Acetylcholine Binding Receptor Positivity from Passive Antibody Transfer in a Case of Progressive Muscular Atrophy (P11-11.009).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
156. WEBER A, Rose J, DeWitt L
     NMOSD: Previously Seropositive Patient Presents with Seronegative Brainstem Attack (P11-14.017).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
157. LOBAINA M, Valaparla VL, Shanina E
     Vogt-Koyanagi-Harada Disease an Autoimmune Comorbidity of Multiple Sclerosis, Not Just a Mimicker (P3-14.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
158. HABIB AA, Kaminski HJ, Grosskreutz J, Mantegazza R, et al
     Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
159. KARAYI G, Quinones-Herrero N, Martin J, Chaudhry S, et al
     A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
160. ROSE M, Hsu S, Balan A, Anderson A, et al
     Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study (P4-6.014).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
161. JAFFRY K, Karpenos S, Lin J, Matos J, et al
     Climate Change Associated with Declining Clinical Outcomes in Myasthenia Gravis for US States with the Greatest Temperature Increase (P4-14.004).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
162. MAKAROVA A, Raju S, Ciotti J
     Parainfectious Hemorrhagic Longitudinally-extensive Transverse Myelitis Secondary to COVID-19 (P1-13.010).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
163. WOODSON S, Gettings E, Guo CY, Klineova S, et al
     Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
164. VARNET M, Kayani S, Wang C
     Diagnostic Journey and Therapeutic Intervention of a Type-1 Interferonopathy in a Newborn (P6-8.002).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     
165. MIKAMI T, Levy M
     Association of HLA-DRB1*15:01 Status with Transcriptomic Pattern of B cells in CSF in Multiple Sclerosis (P7-6.011).
     Neurology. 2024;102.
     PubMed     Abstract available
     
     
     March 2024
166. YOUNG A, Johnston JL
     Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
     Neurology. 2024;102:e209260.
     PubMed     Abstract available
     
     
     
167. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
     Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
     Neurology. 2024;102:e209130.
     PubMed     Abstract available
     
     
     
168. MARRIE RA, Salter A
     Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
     Neurology. 2024;102:e208099.
     PubMed    
     
     
     
169. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
     Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e208032.
     PubMed     Abstract available
     
     
     
170. BOURDETTE D, Wooliscroft L
     The Challenges of Treating Late-Onset Multiple Sclerosis.
     Neurology. 2024;102:e209146.
     PubMed    
     
     
     
171. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
     Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
     Neurology. 2024;102:e208051.
     PubMed     Abstract available
     
     
     
172. 
     Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e209252.
     PubMed    
     
     
     
173. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
     Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
     Neurology. 2024;102:e209135.
     PubMed     Abstract available
     
     
     
174. CHARD DT
     Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
     Neurology. 2024;102:e209246.
     PubMed    
     
     
     
175. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
     Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
     Neurology. 2024;102:e208058.
     PubMed     Abstract available
     
     
     
176. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
     Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
     Neurology. 2024;102:e209147.
     PubMed     Abstract available
     
     
     February 2024
177. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
     Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
     Neurology. 2024;102:e208019.
     PubMed     Abstract available
     
     
     
178. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
     Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
     Neurology. 2024;102:e208100.
     PubMed     Abstract available
     
     
     
179. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
     Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
     Neurology. 2024;102:e209153.
     PubMed    
     
     
     
180. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
     Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
     Neurology. 2024;102:e207966.
     PubMed     Abstract available
     
     
     
181. WU J, Guo K, Liu J
     Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
     Neurology. 2024;102:e208064.
     PubMed     Abstract available
     
     
     
182. NG HS, Zhu F, Zhao Y, Yao S, et al
     Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
     Neurology. 2024;102:e208006.
     PubMed     Abstract available
     
     
     
183. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
     Patient With Rigidity and Fasciculations.
     Neurology. 2024;102:e208110.
     PubMed     Abstract available
     
     
     
184. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
     Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
     Neurology. 2024;102:e208059.
     PubMed     Abstract available
     
     
     January 2024
185. GIBSON S, Mcgraw C
     Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
     Neurology. 2024;102:e208027.
     PubMed     Abstract available
     
     
     
186. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
     Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
     Neurology. 2024;102:e207937.
     PubMed     Abstract available
     
     
     
187. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
     Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
     Neurology. 2024;102:e207916.
     PubMed     Abstract available
     
     
     
188. HABIB AA, Sacks N, Cool C, Durgapal S, et al
     Hospitalizations and Mortality From Myasthenia Gravis.
     Neurology. 2024;102:e207863.
     PubMed     Abstract available
     
     
     
189. LANGER-GOULD A, Sotirchos ES, Bourdette D
     Rituximab for Multiple Sclerosis.
     Neurology. 2024;102:e208063.
     PubMed     Abstract available
     
     
     
190. GALETTA S, Brownlee W
     Assignment Completed.
     Neurology. 2024;102:e207913.
     PubMed     Abstract available
     
     
     
191. TUR C, Rocca MA
     Progression Independent of Relapse Activity in Multiple Sclerosis.
     Neurology. 2024;102:e207936.
     PubMed     Abstract available
     
     
     
192. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
     Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
     Neurology. 2024;102:e200805.
     PubMed     Abstract available
     
     
     
193. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
     Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
     Neurology. 2024;102:e207768.
     PubMed     Abstract available
     
     
     
194. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
     Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
     Neurology. 2024;102:e207965.
     PubMed     Abstract available
     
     
     
195. ALKABIE S, Gray MT, Lau JC, Barra L, et al
     Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
     Neurology. 2024;102:e208018.
     PubMed     Abstract available
     
     
     December 2023
196. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
     Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
     Neurology. 2023;101:e2483-e2496.
     PubMed     Abstract available
     
     
     
197. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
     Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
     Neurology. 2023;101:e2585-e2588.
     PubMed     Abstract available
     
     
     
198. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
     Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
     Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
     PubMed     Abstract available
     
     
     November 2023
199. LI X, Stitt D, Lanzino G, Giannini C, et al
     Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
     Neurology. 2023;101:979-980.
     PubMed    
     
     
     October 2023
200. SRIVASTAVA I, Van Haren K
     Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
     Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
     PubMed    
     
     
     
201. BOURDETTE D, Silbermann E
     What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
     Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
     PubMed    
     
     
     
202. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
     Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
     Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
     PubMed     Abstract available
     
     
     
203. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
     Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
     Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
     PubMed     Abstract available
     
     
     
204. GUASP M, Dalmau J
     Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
     Neurology. 2023;101:656-660.
     PubMed     Abstract available
     
     
     
205. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
     Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
     Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
     PubMed     Abstract available
     
     
     
206. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
     Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
     Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
     PubMed     Abstract available
     
     
     September 2023
207. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
     Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
     Neurology. 2023;101:e1280-e1292.
     PubMed     Abstract available
     
     
     
208. PALLADINO R, Strijbis EM
     How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
     PubMed    
     
     
     
209. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
     Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
     PubMed     Abstract available
     
     
     
210. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
     Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
     Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
     PubMed     Abstract available
     
     
     
211. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
     Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
     Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
     PubMed     Abstract available
     
     
     
212. BUYUKKURT A, Harroud A
     The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
     Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
     PubMed    
     
     
     July 2023
213. QUINN C, Moulton K, Farwell M, Le W, et al
     Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
     PubMed     Abstract available
     
     
     
214. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
     Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
     PubMed     Abstract available
     
     
     
215. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
     Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
     Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
     PubMed     Abstract available
     
     
     September 2022
216. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
     Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
     Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
     PubMed     Abstract available
     
     
     August 2022
217. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
     Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
     Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.